Weiye Deng, M.D., MPH
Weiye Deng, M.D., MPH, obtained her medical degree in China. During her training in surgical oncology at Sun Yat-sen University Cancer Center, her research focused on investigating prognosis factors for patients with head and neck cancer. After her clinical training, Dr. Deng pursued a Master of Public Health degree at UTHealth School of Public Health to strengthen her skills on data analysis and health services research.
Meanwhile, she worked as a graduate research assistant in the Department of Radiation Oncology at MD Anderson Cancer Center. During this time, her research focused on lung and esophageal cancer where she, along with her colleagues, identified a prognostic scoring model for esophageal cancer patients who underwent induction chemotherapy prior to neoadjuvant chemoradiotherapy (Journal of Thoracic Oncology, 2017). Dr. Deng applied a heat-mapping approach and built simplified prognostic scoring models in patients with resected N2 non-small cell lung cancer using the SEER database (Journal of Thoracic Oncology, 2018). Dr. Deng also explored the utility of log odds of positive lymph nodes as a prognostic factor for non-small cell lung cancer patients (Lung Cancer, 2018). In September 2018, she joined the Jiang Lab to work on translational research related to cancer immunotherapy and radiation therapy.
Deng W, Xu T, Wang Y, Xu Y, Yang P, Gomez D, Liao Z. Log odds of positive lymph nodes may predict survival benefit in patients with node-positive non-small cell lung cancer. Lung Cancer. 2018 Aug;122:60-66.
Deng W, Xu T, Xu Y, Wang Y, Liu X, Zhao Y, Yang P, Liao Z. Survival patterns for patients with resected N2 non-small cell lung cancer and postoperative radiotherapy: a prognostic scoring model and heat map approach. J Thorac Oncol. 2018 Dec;13(12):1968-1974. (Highlighted and discussed by an editorial in the same issue, 2018 Dec;13(12):1809-1811)
Xi M, Liao Z, Deng W, Cai Xu, Komaki RU, Blum B, Hofstetter WL, Ho L, Lin SH. A prognostic scoring model for the utility of induction chemotherapy prior to neoadjuvant chemoradiotherapy in esophageal cancer. J Thorac Oncol. 2017 June;12(6):1001-1010.
Xi M, Liao Z, Deng W, Komaki RU, Ho L, Lin SH. Recursive partitioning analysis identifies pretreatment risk groups for the utility of induction chemotherapy before definitive chemoradiation therapy in esophageal cancer. Int J Radiat Oncol Biol Phys. 2017 Oct;99(2):407-416.
Yifan Wang, Ph.D.
Yifan Wang, Ph.D., earned his bachelor’s degree with honours from China Agricultural University in 2013 and his Ph.D. from University of Texas MD Anderson Cancer Center in 2018. Under the mentorship of Dr. Steven Lin, his graduate research focused on the development of novel therapeutic strategies to enhance the treatment efficacy for lung cancer radiotherapy. Dr. Wang and colleagues identified that HSP90 inhibitor ganetespib and MEK inhibitor trametinib sensitized lung cancer cells to chemoradiation, but the efficacy depended on the genetic background of the cell (Clinical Cancer Research, 2016; Clinical Cancer Research, 2018). In another project, they identified that RAD50 expression predicted radioresistance and could be a potential therapeutic target (Clinical Cancer Research, 2017).
In the senior years of graduate school, Dr. Wang’s research interest turned toward immunotherapy, where he worked under the supervision of Wen Jiang, M.D., Ph.D. in several projects aimed to increase antitumor immunity by regulating macrophage phagocytosis. They discovered that targeting calreticulin-LRP1 axis by designer therapy increased phagocytosis by macrophages and induced downstream T cell activation (Nature Nanotechnology, 2017). Dr. Wang received several awards during his graduate study, including the President’s Research Scholarship, the T.C. Tsu Memorial Scholarship, and the Scholarship for Excellence in Biochemistry at MD Anderson, as well as a travel award from the Radiation Research Society. In August 2018, after graduation from MD Anderson, he joined the Jiang Lab as a postdoctoral researcher where his research is focused on cancer immunotherapy. Dr. Wang’s current research project is investigating the interaction between nanomedicine and immune cells and its implications for cancer therapy.
Wang Y, Liu Z, Yuan H, Deng W, Huang Y, Li J, Kim BYS, Story MD, Jiang W. The reciprocity between radiotherapy and cancer immunotherapy. Clin Cancer Res. 2018 Nov 9. doi: 10.1158/1078-0432.CCR-18-2581. (published online first)
Wang Y, Li N, Jiang W, Deng W, Ye R, Xu C, Qiao Y, Sharma A, Zhang M, Hung MC, Lin SH, Mutant LKB1 confers enhanced radiosensitization in combination with trametinib in KRAS-mutant non-small cell lung cancer. Clin Cancer Res. Aug 2018 1. doi: 10.1158/1078-0432.CCR-18-1489.
Wang Y, Gudikote J, Yan J, Deng W, Jiang W, Li N, Ye R, Hobbs BP, Wang J, Swisher SG, Fujimoto J, Wistuba II, Komaki R, Heymach JV, Lin SH. RAD50 expression is associated with poor clinical outcomes after radiotherapy in resected non-small cell lung cancer. Clin Cancer Res. 2018 Jan 15;24(2):341-350.
Wang Y, Liu H, Diao L, Potter A, Zhang J, Qiao Y, Wang J, Proia DA, Tailor R, Komaki R, Lin SH. Hsp90 inhibitor ganetespib sensitizes non-small cell lung cancer to radiation but has variable effects with chemoradiation. Clin Cancer Res. 2016 Dec 1;22(23):5876-5886.
Zhaogang Yang, Ph.D.
Zhaogang Yang, Ph.D., received his B.S. in pharmaceutical sciences (2003) and M.S. in pharmaceutics (2006) from Peking University, China. Following that, he completed an M.S. in pharmacology (2010) and a Ph.D. in pharmaceutical sciences (2012) at Ohio State University. After that he worked as a post doctor at the Mayo Clinic, then as a research associate at Ohio State University.
Dr. Yang's research interests focus on the application of nanotechnology in drug delivery, including novel nanoparticle-based cancer detection, gene delivery and cancer therapy, and nanoelectroporation in gene therapy. He has authored three book chapters, more than 70 peer-reviewed journal papers, seven conference abstracts, and two patents. He is a consultant editor of the International Journal of Nanomedicine and a guest editor for Current Organic Synthesis, Dose-Response, Frontiers in Bioscience, European Journal of BioMedical Research, and Molecules special issues.
Mingming Yang received her bachelor's degree in medical science in 2011 from Anhui Medical University and an M.S. from Peking University in 2014. She completed her master's degree at the Institute of Biophysics, Chinese Academy of Sciences. During that time, her research focused on the immunological regulation of normal or pathological pregnancies. She found that hormones during pregnancy might influence the development and differentiation of plasmacytoid dendritic cells (pDC), which plays an important role of presenting antigens (Journal of Reproductive Medicine, 2015). In addition, she was motivated to discover if a pregnancy-specific hormone (hCG) might be regulated immunologically.
After that, she continued to work at the Institute of Biophysics, Chinese Academy of Sciences as a research assistant focusing on tumor immunotherapy. She and her colleagues found that the combination treatment of traditional antibody and TLR-L was advantageous over a single treatment. Further mechanism indicated monocyte-derived DC promotes anti-tumor T cells to attack tumor cells.
In 2016, she joined UTSW's Pathology Department as a research assistant. During that time, she focused on basic research of epigenetic regulation on DNA repair. In August 2019, she joined Dr. Jiang’s lab to work on the interaction between nanomedicine and immune cells and its implications of cancer therapy.
Mingming Y, Lingling Y, Xiaoye W, Yan W, Yuan W, Yangyu Z. Declination of plasmacytoid dendritic cells and its subsets in normal pregnancy are related with hormones. Journal of Reproductive Medicine. 2015 Sep-Oct;60(9-10):423-429.
Mingming Y, Yuan W, Yangyu Z. An insight into the dendritic cells in gestation and its regulation by hormones. Chinese Journal of Clinical Obstetrics and Gynecology. 2014,15(3):281-282.